Recalibrating Interpretations of Aldosterone Assays Across the Physiologic Range: Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry Measurements Under Multiple Controlled Conditions
Overview
Affiliations
Context: Clinicians frequently rely on aldosterone thresholds derived from older immunoassays to diagnose primary aldosteronism. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is increasingly widespread and reported to yield lower aldosterone concentrations.
Objective: Given the health impact of incorrect interpretations of aldosterone levels, we compared measurements using LC-MS/MS and immunoassay across the full range of aldosterone physiology by evaluating distinct regulation by angiotensin II and adrenocorticotropin (ACTH).
Methods: Normotensive volunteers underwent prospective characterization of aldosterone production by immunoassay and LC-MS/MS during 4 conditions (n = 188): oral sodium suppression and restriction (to assess angiotensin II-mediated aldosterone production) and dexamethasone suppression and cosyntropin stimulation (to assess ACTH-mediated aldosterone production).
Results: Serum aldosterone concentrations by LC-MS/MS and immunoassay had a correlation of 0.69 ( < .001), with good agreement (intraclass correlation 0.76; 95% CI 0.52-0.87). Aldosterone was lower by LC-MS/MS than immunoassay (median 10.5 [3.8, 21.9] vs 19.6 [9.5, 28.0] ng/dL; < .001), with an average difference of 37.2%. The most notable discrepancy was in the clinically discriminatory range <20 ng/dL: 9.9 (7.1, 13.8) ng/dL using immunoassay corresponded to 5.5 (1.4, 8.9) ng/dL by LC-MS/MS ( < .001). Following oral sodium suppression, the aldosterone-to-renin ratio was 4-fold higher using immunoassay (27.2 [19.7, 62.4] vs 6.4 [3.5, 19.1] ng/dL per ng/mL/hour; < .001).
Conclusion: Aldosterone measurements are substantially lower by LC-MS/MS than immunoassay across the full physiologic range, especially when aldosterone levels were less than 20 ng/dL. These findings highlight the need to recalibrate diagnostic interpretations when measuring aldosterone via LC-MS/MS and provide insights into potential biologic causes of assay differences.
Characterizing the Origins of Primary Aldosteronism.
Brown J, Honzel B, Tsai L, Milks J, Neibuhr Y, Neibuhr Y Hypertension. 2024; 82(2):306-318.
PMID: 39660429 PMC: 11735322. DOI: 10.1161/HYPERTENSIONAHA.124.24153.
Saline suppression testing-induced hypocalcemia and implications for clinical interpretations.
Parksook W, Brown J, Milks J, Tsai L, Chan J, Moore A Eur J Endocrinol. 2024; 191(2):241-250.
PMID: 39073780 PMC: 11322817. DOI: 10.1093/ejendo/lvae099.
Ono Y, Tezuka Y, Omata K, Morimoto R, Yamazaki Y, Oguro S J Endocr Soc. 2024; 8(6):bvae080.
PMID: 38715590 PMC: 11074589. DOI: 10.1210/jendso/bvae080.
Knuchel R, Erlic Z, Gruber S, Amar L, Larsen C, Gimenez-Roqueplo A Front Endocrinol (Lausanne). 2024; 15:1370525.
PMID: 38596218 PMC: 11002274. DOI: 10.3389/fendo.2024.1370525.
Tezuka Y, Omata K, Ono Y, Kambara K, Kamada H, Oguro S Hypertens Res. 2024; 47(5):1362-1371.
PMID: 38454147 PMC: 11073978. DOI: 10.1038/s41440-024-01594-x.